Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

The microbial metabolite agmatine induces polycystic ovary syndrome in mice

Agmatine produced by gut microbiota — specifically, Bacteroides vulgatus — activates the farnesoid X receptor (FXR) in intestinal epithelial L cells in a bile-acid-independent manner, which inhibits host glucagon peptide 1 (GLP-1) secretion and leads to polycystic ovary syndrome (PCOS) in mice. Supplementing mice with the GLP-1 receptor (GLP-1R) agonist liraglutide or inhibiting the production of agmatine reverses the PCOS phenotype.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The GLP-1R agonist liraglutide reverses the B.-vulgatus-induced PCOS-like phenotype in mice.

References

  1. Qi, X. et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat. Med. 25, 1225–1233 (2019). This paper reports on the mechanism of how B. vulgatus induces PCOS through the bile-acid–IL-22 pathway.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Trabelsi, M.-S. et al. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat. Commun. 6, 7629 (2015). This paper reports on the FXR–GLP-1 pathway in enteroendocrine L cells.

    Article  PubMed  Google Scholar 

  3. Jensterle, M. et al. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum. Reprod. Update 25, 504–517 (2019). A review that presents the potential role of GLP-1 in the pathogenesis and treatment of PCOS.

    Article  CAS  PubMed  Google Scholar 

  4. Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 27, 740–756 (2018). A review that presents the mechanisms of action, side effects and applications of existing GLP-1R agonists.

    Article  CAS  PubMed  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Yun, C. et al. The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice. Nat. Metab. https://doi.org/10.1038/s42255-024-01041-8 (2024).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

The microbial metabolite agmatine induces polycystic ovary syndrome in mice. Nat Metab 6, 791–792 (2024). https://doi.org/10.1038/s42255-024-01040-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-024-01040-9

Search

Quick links

Nature Briefing Microbiology

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing: Microbiology